Table 2.
Demographic characteristics of participants receiving antithrombotic therapy.
| Number of Participants with Antithrombotic Treatment | |
|---|---|
| n = 34 | |
| Sex, n (%) | |
| Female | 22 (64.7) |
| Age, median (range) | 79.5 (72–82) |
| BMI, median (range) | 23.4 (21–29) |
| Smoking status, n (%) | |
| Former smoker/non-smoker | 21 (61.8) |
| Current smoker | 12 (35.3) |
| Missing value | 1 (2.9) |
| GOLD stage, n (%) | |
| GOLD 1 | 2 (5.9) |
| GOLD 2 | 11 (32.4) |
| GOLD 3 | 16 (47.1) |
| GOLD 4 | 2 (5.9) |
| Missing value | 3 (8.8) |
| Comorbidities, n (%) | |
| Diabetes mellitus | 5 (14.7) |
| Asthma | 7 (20.6) |
| Atrial fibrillation | 18 (52.9) |
| Previous VTE | 7 (20.6) |
| Essential hypertension | 21 (61.8) |
| Previous cancer | 3 (8.8) |
| Medication, n (%) | |
| Anticoagulant therapy | 22 (64.7) |
| Antiplatelet therapy | 12 (35.3) |
Abbreviations: VTE, venous thromboembolism.